# Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients

> **NCT01335698** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 160 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Atazanavir Sulphate
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01335698
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-27
- **Primary completion:** 2014-09-10
- **Final completion:** 2018-01-22
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2018-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01335698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01335698, "Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01335698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*